Interleukin-6 is a positive regulator of tumor necrosis factor α-induced adipose-related protein in 3T3-L1 adipocytes  by Fasshauer, Mathias et al.
Interleukin-6 is a positive regulator of tumor necrosis factor K-induced
adipose-related protein in 3T3-L1 adipocytes
Mathias Fasshauera;1, Susan Kralischa;1, Margit Kliera, Ulrike Lossnera, Matthias Bluhera,
Anne-Marie Chambaut-Gue¤rinb, Johannes Kleinc, Ralf Paschkea;
aUniversity of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
bUMR 7079 CNRS, Universite¤ Pierre et Marie Curie, Centre de Recherche Biome¤dicale des Cordeliers, 15 rue de l’Ecole de Me¤decine,
75270 Paris Cedex 06, France
cUniversity of Lu«beck, Department of Internal Medicine I, 23538 Lu«beck, Germany
Received 23 December 2003; revised 19 January 2004; accepted 22 January 2004
First published online 4 February 2004
Edited by Robert Barouki
Abstract Tumor necrosis factor (TNF) K-induced adipose-re-
lated protein (TIARP) is a novel TNFK-stimulated protein in
adipocytes. Besides TNFK, interleukin (IL)-6 has recently been
shown to be another adipocytokine implicated in insulin resis-
tance. Therefore, the impact of IL-6 on TIARP gene expression
in 3T3-L1 adipocytes was determined by quantitative real-time
reverse transcription-polymerase chain reaction. Interestingly,
TIARP mRNA expression was stimulated up to 3.8-fold by
IL-6 in a dose-dependent fashion with signi¢cant stimulation
detectable at e¡ector concentrations as low as 3 ng/ml and
maximal e¡ects seen at 100 ng/ml IL-6. Induction of TIARP
mRNA by IL-6 was time-dependent with signi¢cant upregula-
tion occurring as early as 2 h after e¡ector addition and max-
imal e¡ects observed at 4 h. In parallel, TIARP protein syn-
thesis was upregulated with maximal e¡ects seen after 8 h of
IL-6 treatment. Furthermore, the Janus kinase 2 inhibitor
AG490 decreased TIARP mRNA expression. The increase of
TIARP mRNA could be reversed by withdrawal of IL-6 for
24 h. Furthermore, TIARP mRNA induction by IL-6 was also
seen in brown adipocytes but not in muscle and liver cells.
Taken together, these results show that TIARP is acutely regu-
lated in adipose tissue not only by TNFK but also by IL-6 which
has been shown to be another important cytokine implicated in
the pathogenesis of insulin resistance.
4 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Obesity-associated insulin resistance is an important risk
factor in the development of atherosclerosis, hypertension,
and type 2 diabetes [1]. The connection between insulin resis-
tance and increased body weight is unclear. However, recent
studies suggest that adipocytes secrete various biologically ac-
tive proteins which in£uence insulin sensitivity thereby alter-
ing glucose homeostasis. Among those so-called adipocyto-
kines, tumor necrosis factor (TNF) K [2], interleukin (IL)-6
[3], and resistin [4] have been suggested to induce insulin re-
sistance whereas adiponectin [5] appears as an endogenous
insulin sensitizer. Elucidating downstream signaling molecules
of these adipocytokines has become a focus of current re-
search since novel targets for the treatment of insulin resis-
tance and associated metabolic disorders might arise from
these studies. Recently, in an elegant experimental setting, a
novel TNFK-responsive gene was cloned from fat cells by
di¡erential display technique [6]. It was named TNFK-induced
adipose-related protein (TIARP), and the authors demon-
strated convincingly that it is induced by TNFK in a dose-
and time-dependent fashion and during adipogenic conversion
[6]. Furthermore, TIARP is a transmembrane protein prefer-
entially present at the plasma membrane and its general struc-
ture is reminiscent of various channels or transporters [6].
Although the biological function of TIARP is presently un-
known, these data suggest that this protein might participate
in adipocyte maturation and metabolism and may mediate
TNFK e¡ects on fat cells. However, a potential regulation
of TIARP gene expression by other important adipocytokines
with profound e¡ects on insulin sensitivity has not been elu-
cidated so far.
In the current study, we, therefore, examined the e¡ect of
IL-6 on TIARP synthesis in vitro. We demonstrate for the
¢rst time that IL-6 potently and reversibly induces TIARP
expression in fat cells.
2. Materials and methods
2.1. Materials
AG490, dexamethasone, IL-6, isobutylmethylxanthine, LY294002,
PD98059, and SB203580 were obtained from Sigma Chemical Co. (St.
Louis, MO, USA), insulin from Roche Molecular Biochemicals
(Mannheim, Germany). Cell culture reagents were purchased from
Life Technologies, Inc. (Grand Island, NY, USA), oligonucleotides
from MWG-Biotech (Ebersberg, Germany).
2.2. Cell culture and di¡erentiation
3T3-L1 cells (American Type Culture Collection, Rockville, MD,
USA) were grown and di¡erentiated into adipocytes as previously
described [7]. In brief, preadipocytes were grown to con£uence in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 25 mM
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glucose, 10% fetal bovine serum, and antibiotics (culture medium).
Con£uent cells were induced for 3 days in culture medium further
supplemented with 1 WM insulin, 0.5 mM isobutylmethylxanthine,
and 0.1 WM dexamethasone before they were maintained for another
3 days in culture medium with 1 WM insulin and for additional 4^8
days in culture medium. After this period, more than 90% of the cells
showed fat droplet accumulation. Brown adipocytes and C2C12 myo-
cytes were cultured and di¡erentiated as described recently [8,9].
2.3. Analysis of TIARP gene expression
TIARP mRNA was quanti¢ed by real-time reverse transcription-
polymerase chain reaction (RT-PCR) in a £uorescent temperature
cycler (LightCycler, Roche Molecular Biochemicals, Mannheim, Ger-
many) as previously described [10]. In brief, total RNA was isolated
with Trizol reagent (Life Technologies, Inc., Grand Island, NY,
USA), reverse transcribed in a 20 Wl reaction using standard reagents
(Life Technologies, Inc., Grand Island, NY, USA), and 10% of each
RT reaction was loaded into capillary tubes. Ampli¢cation was per-
formed in a 20 Wl PCR containing 3 mM MgCl2, 0.5 WM each primer
and 1U LightCycler DNA Master SYBR Green I mix (Roche Mo-
lecular Biochemicals, Mannheim, Germany) using the following PCR
parameters: An initial denaturation at 94‡C for 30 s, followed by 40
PCR cycles, each consisting of 95‡C for 1 s, 61‡C for 7 s, and 72‡C for
11 s. The following primers were used: TIARP (accession number
AJ319746) TAGGGTGTAGGCGAGCAGCAGT (sense) and TCA-
GTGACACGCGGGAAGATT (antisense); 36B4 (accession number
NM007475) AAGCGCGTCCTGGCATTGTCT (sense) and CCGC-
AGGGGCAGCAGTGGT (antisense). After each cycle, SYBR Green
I £uorescence emission readings were monitored and TIARP, as well
as 36B4 mRNA levels, were quanti¢ed by the second derivative max-
imum method of the LightCycler Software (Roche Molecular Bio-
chemicals, Mannheim, Germany). Brie£y, the crossing points of indi-
vidual samples were determined by an algorithm identifying the ¢rst
turning point of the £uorescence curve. TIARP expression was calcu-
lated relative to 36B4 which has been frequently used as an internal
control due to its resistance to hormonal regulation [11].
Ampli¢cation of speci¢c transcripts was con¢rmed by melting curve
pro¢les (cooling the sample to 68‡C and heating slowly to 95‡C with
continuous measurement of £uorescence) at the end of each PCR and
by subjecting the ampli¢cation products to agarose gel electrophore-
sis.
2.4. Western blotting
Detection of TIARP synthesis by Western blotting was performed
essentially as described previously [12]. Brie£y, after the stimulation
period cells were harvested in lysis bu¡er (50 mM HEPES, 137 mM
NaCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM Na4P2O7, 10 mM NaF,
2 mM ethylenediamine tetraacetic acid (EDTA), 10% glycerol, 1%
Igepal CA-630, 2 mM vanadate, 10 Wg/ml leupeptin, 10 Wg/ml apro-
tinin, 2 mM phenylmethylsulfonyl £uoride, pH 7.4). Lysates were
clari¢ed and equal amounts of protein were solubilized in Laemmli
sample bu¡er. Proteins were resolved by sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE), transferred to nitrocel-
lulose membranes, blocked for 1 h, and immunoblotted with TIARP
antibody [6]. Speci¢cally bound primary antibodies were detected with
peroxidase-coupled secondary antibody and enhanced chemilumines-
cence.
2.5. Statistical analysis
Results are expressed as meansRS.E.M. Di¡erences between vari-
ous cell treatments were analyzed by unpaired Student’s t-tests. P
values 6 0.01 are considered highly signi¢cant, 6 0.05 signi¢cant.
3. Results
3.1. IL-6 stimulates TIARP mRNA and protein expression in
3T3-L1 adipocytes
Since it has recently been shown that TIARP mRNA ex-
pression is upregulated by TNFK, we tested whether the adi-
pocytokine IL-6 might in£uence TIARP synthesis in 3T3-L1
adipocytes in vitro. In fact, IL-6 stimulated TIARP gene ex-
pression in a dose-dependent fashion. Thus, a signi¢cant 1.9-
fold induction of TIARP mRNA synthesis was detectable at
IL-6 concentrations as low as 3 ng/ml (P6 0.01) (Fig. 1). A
maximal 3.8-fold increase was found at 100 ng/ml of the adi-
pocytokine (P6 0.01) (Fig. 1). Furthermore, 30 ng/ml IL-6
upregulated TIARP mRNA time dependently with signi¢cant
2.7-fold stimulation detectable as early as 2 h after e¡ector
addition, a maximal 3.2-fold induction after 4 h of hormone
treatment, and stimulation persisting for up to 24 h (P6 0.01)
(Fig. 2A). Moreover, TIARP protein expression was upregu-
lated time dependently with maximal stimulation seen after 8 h
of IL-6 incubation (Fig. 2B).
3.2. IL-6 induces TIARP mRNA in brown adipocytes but not in
C2C12 myocytes
Next, we determined whether IL-6 upregulated TIARP
mRNA in other insulin-sensitive tissues. Similar to 3T3-L1
cells, IL-6 induced TIARP mRNA expression in di¡erentiated
brown adipocytes time dependently with signi¢cant 3.3-fold
stimulation seen as early as 1 h after e¡ector addition and a
maximal almost 10-fold increase detectable after 24 h
(P6 0.05) (Fig. 2C). In contrast, no induction of TIARP
mRNA expression was detected when C2C12 myocytes were
treated with IL-6 (Fig. 2D). Moreover, mRNA expression of
the human TIARP homolog was not altered by IL-6 in
HepG2 liver cells (data not shown).
3.3. Stimulation of TIARP gene expression by IL-6 is
reversible
We determined whether the stimulatory e¡ect of IL-6 on
TIARP gene expression was reversible. Fully di¡erentiated
3T3-L1 adipocytes were treated with IL-6 (30 ng/ml) for 16
h, and the medium was then replaced by DMEM containing
25 mM glucose with (Fig. 3A) or without (Fig. 3B) 10% fetal
bovine serum (FBS) for an additional 24 h. Addition of IL-6
again increased TIARP mRNA expression more than 3-fold
as compared to untreated control cells (Fig. 3A and B, col-
umns 1 and 2). However, removal of IL-6 from the medium
for 24 h decreased TIARP mRNA expression to control levels
(Fig. 3A and B, columns 3 and 4). Interestingly, addition of
serum-containing medium for an additional 24 h stimulated
TIARP gene expression more than 2-fold (Fig. 3A, columns 1
Fig. 1. Dose-dependent stimulation of TIARP gene expression by
IL-6. 3T3-L1 adipocytes were serum-starved for 6 h before the indi-
cated concentrations of IL-6 were added for 16 h. Total RNA was
isolated and TIARP mRNA expression normalized to 36B4 was de-
termined by quantitative real-time RT-PCR as described in Section
2. Data are given relative to untreated control (Con) cells ( = 100%).
Results are the meansRS.E.M. of three independent experiments.
**P6 0.01 comparing IL-6-treated with non-treated cells.
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and 3), an e¡ect which was not detectable in the absence of
FBS (Fig. 3B, columns 1 and 3).
3.4. The Janus kinase (Jak) 2 inhibitor AG490 downregulates
TIARP mRNA expression
We tested whether signaling proteins such as Jak2, p44/42
mitogen-activated protein (MAP) kinase, p38 MAP kinase,
and phosphatidylinositol (PI) 3-kinase, which have been impli-
cated in IL-6 signaling, may play a role in upregulation of
TIARP gene expression. For this purpose, 3T3-L1 adipocytes
were pretreated with speci¢c pharmacological inhibitors for 1 h
before IL-6 (30 ng/ml) was added for 16 h. The Jak2 inhibitor
AG490 alone (10 WM) signi¢cantly downregulated basal
TIARP mRNA expression to 29% of the levels seen in un-
treated control cells (P6 0.01) (Fig. 4). In contrast, inhibition
of p44/42 MAP kinase, p38 MAP kinase, and PI 3-kinase with
PD98059 (50 WM), SB203580 (20 WM), and LY294002 (10
WM), respectively, did not signi¢cantly in£uence basal TIARP
mRNA synthesis (Fig. 4). Again, TIARP mRNA was upre-
gulated to 436% of control levels after 16 h of IL-6 treatment
(P6 0.01) (Fig. 4). Interestingly, inhibition of Jak2 by AG490
signi¢cantly reversed this stimulation by almost 70^137% of
the expression level seen in untreated adipocytes (P6 0.01)
(Fig. 4). In contrast, inhibition of p44/42 MAP kinase, p38
MAP kinase, and PI 3-kinase did not signi¢cantly in£uence
induction of TIARP gene expression by IL-6 (Fig. 4).
4. Discussion
Recently, TIARP was described by Moldes et al. as a novel
protein strongly induced by TNFK and adipose conversion
which might mediate some e¡ects of TNFK on insulin sensi-
tivity and adipose metabolism [6]. In the current study, we
demonstrate for the ¢rst time that IL-6 is another potent
stimulator of TIARP expression in insulin-sensitive white
and brown adipocytes. This induction appears to be tissue-
speci¢c since no stimulatory e¡ect is observed in muscle and
liver cells.
IL-6 is a proin£ammatory cytokine, and it has been shown
that plasma concentrations of this protein correlate with the
development of type 2 diabetes mellitus [3,13]. IL-6 is also
regarded an adipocytokine since about 25% of systemic IL-6
originates from subcutaneous fat cells in vivo and omental as
compared to subcutaneous adipocytes that secrete even 2- to
3-fold more IL-6 in vitro [14,15]. IL-6 a¡ects glucose metab-
olism profoundly. Thus, administration of recombinant IL-6
in rodent models induces hepatic gluconeogenesis which, in
turn, leads to hyperglycemia and compensatory hyperinsuline-
mia [16]. Moreover, increased glucose levels have been de-
scribed in humans after IL-6 treatment [13]. Recently, direct
e¡ects of IL-6 on insulin signaling molecules such as insulin
receptor substrate (IRS) proteins have been elucidated. These
proteins have been shown to be essential for insulin action
Fig. 2. Time-dependent induction of TIARP synthesis by IL-6. Fully di¡erentiated (A, B) 3T3-L1 adipocytes, (C) brown adipocytes, and (D)
C2C12 myocytes were serum-deprived overnight before 30 ng/ml IL-6 was added for di¡erent periods of time. A, C, D: After total RNA ex-
traction, TIARP synthesis normalized to 36B4 mRNA was determined by quantitative real-time RT-PCR and expressed relative to untreated
controls ( = 100%) as described in Section 2. Results are the meansRS.E.M. of at least three independent experiments. **P6 0.01, *P6 0.05
comparing IL-6-treated with untreated control cells. B: Total protein was isolated and immunoblotted as described in Section 2. A representa-
tive blot of three independent experiments is shown.
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[17,18]. Thus, IL-6, similar to TNFK, decreases IRS-1 and
Glut4 mRNA and protein expression and IRS-1 tyrosine
phosphorylation in 3T3-L1 cells [19,20]. Moreover, Senn et
al. reported impaired insulin signaling and insulin-induced
glycogen synthesis in hepatocytes after IL-6 pretreatment
[21]. However, signaling pathways and proteins mediating
these e¡ects are far from clear. In the current study, we
show upregulation of TIARP by IL-6. Given our ¢ndings,
further experiments speci¢cally stimulating or suppressing
TIARP synthesis are now required to establish whether this
protein might be involved in regulating IL-6- and TNFK-de-
pendent insulin sensitivity and adipocyte metabolism.
Recently, major steps in IL-6 signaling have been eluci-
dated. Thus, it has been shown that IL-6 induces gp130 ho-
modimerization at the plasma membrane [22]. Upon binding
of IL-6, gp130-associated kinases such as Jak1, Jak2, and
Tyk2 become activated and phosphorylate the cytoplasmic
tail of gp130 [23]. In the current study, we show that pharma-
cological inhibition of Jak2 by AG490 inhibits both, basal and
IL-6-induced TIARP mRNA expression but we also demon-
strate that TIARP synthesis is still stimulated by IL-6 in the
presence of AG490. Thus, it is possible that this compound
may have an independent repressive e¡ect on the TIARP pro-
moter and that IL-6 is not able to completely reverse this
e¡ect. Signal transducer and activator of transcription (Stat)
1 and 3, as well as SH2 domain-containing tyrosine phospha-
tase 2, bind to the tyrosine-phosphorylated gp130 and stim-
ulate downstream signaling proteins such as p44/42 MAP
kinase, p38 MAP kinase, and PI 3-kinase [23]. Since pharma-
cological inhibition of p44/42 MAP kinase, p38 MAP kinase,
and PI 3-kinase does not in£uence IL-6-induced TIARP ex-
pression they are probably not involved in TIARP mRNA
regulation by IL-6. Furthermore, a ‘dedi¡erentiation’ or other
toxic e¡ect of IL-6 is unlikely since induction of TIARP syn-
thesis is reversible upon removal of the hormone. Moreover,
preliminary studies do not reveal a strong e¡ect of rosiglita-
zone on the induction of TIARP mRNA by IL-6 (data not
shown).
Taken together, we demonstrate for the ¢rst time a signi¢-
cant induction of TIARP mRNA and protein expression by
IL-6 in 3T3-L1 cells. Furthermore, we present evidence that
the positive e¡ect of IL-6 is reversible. These data indicate
that TIARP expression is acutely and selectively regulated
in adipose tissue by a cytokine implicated in insulin resistance.
Further studies are needed to more clearly de¢ne its function
in insulin sensitivity and adipocyte metabolism.
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